GCG and type 2 diabetes mellitus: The short‐acting exendin‐based glucagon‐like peptide‐1 (GLP1) receptor agonist lixisenatide reduces post‐prandial hyperglycaemia by suppressing glucagon, and by slowing gastric emptying9 in T2D.